Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that its first quarter 2019 revenues grew five percent year over year, driven by strong results across all of its business segments.

The company, headquartered in Waltham, Massachusetts, reported Q1revenues of $6.12 billion, up 5 percent from $5.85 billion during the same period last year, beating average expectations by Wall Street analysts of $6.02 billion. Organic revenue growth was 7 percent, acquisitions contributed 1 percent, and currency effects decreased revenue by 3 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.